Expression and somatic mutation on androgen receptor gene in prostate cancer

International Journal of Urology

Volumn 9, Issue 10, 2002, Pages 545-553

  Segawa, N ^a   Nakamura, M ^b   Shan, L ^b   Utsunomiya, H ^b   Nakamura, Y ^b   Mori, I ^b   Katsuoka, Y ^a   Kakudo, K ^b  

^a OSAKA MEDICAL COLLEGE   (Japan)

^b WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Androgen receptor gene; Gene expression; Japanese population; Mutation; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; ANTIBODY; HORMONE;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA SEQUENCE; GENE EXPRESSION; GENETIC ANALYSIS; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; JAPAN; LYMPH NODE METASTASIS; MALE; MOLECULAR BIOLOGY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE; PROSTATE ADENOCARCINOMA; SAMPLING; SEQUENCE ANALYSIS; SINGLE STRAND CONFORMATION POLYMORPHISM; SOMATIC MUTATION; TUMOR CELL; TUMOR GROWTH; ADENOCARCINOMA; DISEASE COURSE; GENETICS; METABOLISM; METASTASIS; MIDDLE AGED; MUTATION; PATHOLOGY; PROSTATE TUMOR; TUMOR RECURRENCE;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROGNOSIS; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SEQUENCE ANALYSIS, DNA;

EID: 0036433659     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-2042.2002.00514.x     Document Type: Article

References (33)

1. Boring CC, Squires TS, Tong T. Cancer statistics, 1992. CA Cancer J. Clin. 1992;42: 127-8.
2. Coffey D. Androgen action and the sex accessory tissue. In: Knobil E, Neill J (eds). The Physiology of Reproduction. Raven Press, New York, 1988; 1081-119.
3. Tsai M-J, O'Malley B. Mechanism of regulation of gene transcription by steroid receptors. In: Cohen P, Foulkes JG (eds). The Hormonal Control of Regulation of Gene Transcription. Elsevier, Amsterdam, 1991; 101-16.
4. Petrangeli E, Lubrano C, Ortolani F et al. Estrogen receptors: New perspectives in breast cancer management. J. Steroid Biochem. Mol. Biol. 1994;49: 327-31.
5. Parczyk K, Schneider MR. The future of antihormone therapy innovations based on an established principle. J. Cancer Res. Clin. Oncol. 1996;122: 383-96.
6. Takeda H, Akakura K, Masai M, Akimoto S, Yatani R, Shimazaki J. Androgen receptor content of prostate carcinoma cells estimated by immunohistochemistry is related to prognosis of patients with stage D2 prostate carcinoma. Cancer 1996;77: 934-40.
7. Brendler CB, Isaacs JT, Follansbee AL, Walsh PC. The use of multiple variables to predict response to endocrine therapy in carcinoma of the prostate: a preliminary report. J. Urol. 1984;131: 694-700.
8. Trachtenberg J, Walsh PC. Correlation of prostatic nuclear androgen receptor content with duration of response and survival following hormonal therapy in advanced prostate cancer. J. Urol. 1982; 127: 466-71.
9. Pertschuk LP, Schaeffer H, Feldman JG et al. Immuno-staining for prostate cancer androgen receptor in paraffin identifies a subset of men with a poor prognosis. Lab. Invest. 1995;73: 302-5.
10. Sadi MV, Walsh PC, Barrack ER. Immunohistochemical study of androgen receptors in metastatic prostate cancer. Comparison of receptor content and response to hormonal therapy. Cancer 1991;67: 3057-64.
11. Bentel JM, Tilly WD. Androgen receptors in prostate cancer. J. Endocrinol. 1996;151: 1-11.
12. Ruizeveld de Winter JA, Trapman J, Brinkmann AO et al. Androgen receptor heterogeneity in human prostatic carcinomas visualized by immunohistochemistry. J. Pathol. 1990;161: 329-32.
13. Elo JP, Kvist L, Leinonen K et al. Mutated human androgen receptor gene detected in a prostatic cancer patient is also activated by estradiol. J. Clin. Endocrinol. Metab. 1995;80: 3494-500.
14. Suzuki H, Sato N, Watabe Y, Masai M, Seino S, Shimazaki J. Androgen receptor gene mutations in human prostate cancer. J. Steroid Biochem. Mol. Biol. 1993;46: 759-65.
15. Suzuki H, Akakura K, Komiya A, Aida S, Akimoto S, Shimazaki J. Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: Relation to antiandrogen withdrawal syndrome. Prostate 1996;29: 153-8.
16. Gleason DF. Histological grading and clinical staging of prostate carcinoma. In: Tannenbaum M (ed.). Urologic Pathology, the Prostate. Lea and Fedinger, Philadelphia, 1977; 171-97.
17. Gittes RF. Carcinoma of the prostate. N. Engl. J. Med. 1991;324: 236-45.
18. van der Kwast TH, Schalken J, Ruizeveld de Winter JA et al. Androgen receptors in endocrine-resistant human prostate cancer. Int. J. Cancer 1991;48: 189-93.
19. Furuya Y, Sato N, Akakura K et al. Paracrine growth stimulation of androgen-responsive Shionogi Carcinoma 115 by its autonomous subline (Chiba Subline 2). Cancer Res. 1990;50: 4979-83.
20. Newmark JR, Hardy DO, Tonb DC et al. Androgen receptor gene mutations in human prostate cancer. Proc. Natl Acad. Sci. USA 1992;89: 6319-23.
21. Masai M, Sumiya H, Akimoto S et al. Immunohistochemical study of androgen receptor in benign hyperplastic and cancerous human prostates. Prostate 1990;17: 293-300.
22. Sadi MV, Barrack ER. Image analysis of androgen receptor immunostaining in metastatic prostate cancer. Heterogeneity as a predictor of response to hormonal therapy. Cancer 1993;71: 2574-80.
23. Chodak GW, Kranc DM, Puy LA, Takeda H, Johnson K, Chang C. Nuclear localization of androgen receptor in heterogeneous samples of normal, hyperplastic and neoplastic human prostate. J. Urol. 1992;147: 798-803.
24. Magi-Galluzzi C, Xu X, Hlatky L et al. Heterogeneity of androgen receptor content in advanced prostate cancer. Modern Pathol. 1997;10: 839-45.
25. Rinker-Schaeffer CW, Partin AW, Isaacs WB, Coffey DS, Isaacs JT. Molecular and cellular changes associated with the acquisition of metastatic ability by prostatic cancer cells. Prostate 1994;25: 249-65.
26. Gottlieb B, Trifiro M, Lumbroso R, Pinsky L. The androgen receptor gene mutations database. Nucleic Acids Res. 1997;25: 158-62.
27. Tilley WD, Buchanan G, Hickey TE, Bentel JM. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin. Cancer Res. 1996;2: 277-85.
28. Ruijter E, Kaa CVD, Miller G, Ruiter D, Debruyne F, Schalken J. Molecular genetics and epidemiology of prostate carcinoma. Endocrine Rev. 1999;20: 22-45.
29. Kabalin JN, McNeal JE, Johnstone IM, Stamey TA. Serum prostate-specific antigen and the biologic progression of prostate cancer. Urology 1995;46: 65-70.
30. Epstein JI, Carmichael M, Partin AW, Walsh PC. Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of followup. J. Urol. 1993; 149: 1478-81.
31. Takahashi H, Furusato M, Allsbrook WC Jret al. Prevalence of androgen receptor gene mutations in latent prostatic carcinomas from Japanese men. Cancer Res. 1995;55: 1621-4.
32. Schoenberg MP, Hakimi JM, Wang Set al. Microsatellite mutation (CAG24→18) in the androgen receptor gene in human prostate cancer. Biochem. Biophys. Res. Commun. 1994;198: 74-80.
33. Evans BA, Harper ME, Daniells CE, Watts CE, Maten-helia S, Green J. Low incidence of androgen receptor gene mutations in human prostatic tumors using single strand conformation polymorphism analysis. Prostate 1996;28: 162-71.